CIBRA Capital Ltd Purchases Shares of 62,838 Hologic, Inc. $HOLX

CIBRA Capital Ltd acquired a new position in Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 62,838 shares of the medical equipment provider’s stock, valued at approximately $4,681,000. Hologic accounts for 8.0% of CIBRA Capital Ltd’s holdings, making the stock its 6th largest position.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Hologic by 10.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock valued at $2,395,000 after purchasing an additional 3,520 shares during the last quarter. Empowered Funds LLC grew its holdings in shares of Hologic by 27.7% in the first quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock worth $1,081,000 after purchasing an additional 3,790 shares during the last quarter. MAI Capital Management grew its holdings in shares of Hologic by 121.4% in the second quarter. MAI Capital Management now owns 651 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 357 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of Hologic by 5.2% in the second quarter. Prudential Financial Inc. now owns 129,386 shares of the medical equipment provider’s stock worth $8,431,000 after buying an additional 6,431 shares during the period. Finally, XTX Topco Ltd raised its holdings in Hologic by 11.4% during the 2nd quarter. XTX Topco Ltd now owns 14,505 shares of the medical equipment provider’s stock valued at $945,000 after buying an additional 1,490 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Shares of Hologic stock opened at $75.67 on Friday. The business has a 50 day moving average of $75.22 and a 200 day moving average of $73.29. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $75.75. The company has a market cap of $16.89 billion, a PE ratio of 31.53, a P/E/G ratio of 2.25 and a beta of 0.73. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm earned $0.87 EPS. The business’s revenue was up 2.5% on a year-over-year basis. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

HOLX has been the subject of several analyst reports. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Finally, Evercore lowered shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their target price for the stock from $79.00 to $78.00 in a report on Monday, January 5th. Two research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $78.42.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.